MA38661A1 - Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine - Google Patents
Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamineInfo
- Publication number
- MA38661A1 MA38661A1 MA38661A MA38661A MA38661A1 MA 38661 A1 MA38661 A1 MA 38661A1 MA 38661 A MA38661 A MA 38661A MA 38661 A MA38661 A MA 38661A MA 38661 A1 MA38661 A1 MA 38661A1
- Authority
- MA
- Morocco
- Prior art keywords
- heteroaromatic compounds
- preparation
- compounds
- cognitive impairment
- schizophrenia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La présente invention concerne, en partie, des composés représentés par la formule (i) : (i) et leurs sels pharmaceutiquement acceptables ; des procédés pour leur préparation ; des intermédiaires utilisés dans leur préparation ; et des compositions contenant de tels composés ou sels et leurs utilisations pour le traitement de pathologies médiées par le d1 (ou associées au d1), notamment la schizophrénie (par ex., ses symptômes cognitifs et négatifs), le déficit cognitif (par ex., le déficit cognitif associé à la schizophrénie, la ma, la mp ou une pharmacothérapie), le déclin des facultés mentales lié à l'âge, la démence et la maladie de parkinson.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361840144P | 2013-06-27 | 2013-06-27 | |
PCT/IB2014/062217 WO2014207601A1 (fr) | 2013-06-27 | 2014-06-13 | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine |
Publications (1)
Publication Number | Publication Date |
---|---|
MA38661A1 true MA38661A1 (fr) | 2017-03-31 |
Family
ID=51205521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38661A MA38661A1 (fr) | 2013-06-27 | 2014-06-13 | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine |
Country Status (42)
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150291625A1 (en) | 2012-11-08 | 2015-10-15 | Pfizer Inc. | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands |
MX2020013099A (es) | 2013-06-27 | 2022-07-26 | Pfizer | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina. |
KR20160142401A (ko) | 2014-04-25 | 2016-12-12 | 화이자 인코포레이티드 | 도파민 d1 리간드로서 헤테로방향족 화합물 및 이의 용도 |
CR20160494A (es) | 2014-04-25 | 2016-12-20 | Pfizer | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 |
WO2015162518A1 (fr) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Composes hetero-aromatiques et leur utilisation comme ligands d1 de la dopamine |
WO2015166370A1 (fr) | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Composés hétéroaromatiques et leur utilisation en tant que ligands de la dopamine d1 |
JP6564394B2 (ja) | 2014-04-28 | 2019-08-21 | ファイザー・インク | 複素環式化合物およびそのドーパミンd1リガンドとしての使用 |
JOP20150177B1 (ar) | 2014-08-01 | 2021-08-17 | Janssen Pharmaceutica Nv | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 |
CN106146404B (zh) * | 2015-04-15 | 2020-03-20 | 江苏恩华药业股份有限公司 | 哒嗪酮类衍生物及其应用 |
US10392347B2 (en) | 2015-10-14 | 2019-08-27 | Bristol-Myers Squibb Company | 2,4-dihydroxy-nicotinamides as APJ agonists |
DK3389727T3 (da) | 2015-12-18 | 2020-11-02 | Janssen Pharmaceutica Nv | Radioaktivt mærkede mglur2/3-pet-ligander |
JP6929285B2 (ja) | 2015-12-18 | 2021-09-01 | ヤンセン ファーマシューティカ エヌ.ベー. | 放射性標識mGluR2/3PETリガンド |
CA3011201C (fr) * | 2016-01-15 | 2020-09-22 | Pfizer Inc. | Ligands 6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine du recepteur d3 de la dopamine |
AU2017238504B2 (en) | 2016-03-24 | 2021-05-27 | Bristol-Myers Squibb Company | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists |
AU2017244864B2 (en) | 2016-03-30 | 2021-04-22 | Ishihara Sangyo Kaisha, Ltd. | Pyridazinone-type compound or salt thereof, and herbicide comprising same |
JP7046968B2 (ja) * | 2017-03-02 | 2022-04-04 | 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ | 2-(置換フェニルヘテロ)芳香族カルボン酸系fto阻害剤、その製造方法およびその使用 |
EP4139296B1 (fr) | 2020-04-23 | 2024-09-18 | Opna Bio SA | Composés et procédés de modulation de cd73 et leurs indications |
AU2022402852A1 (en) | 2021-12-03 | 2024-06-20 | Teva Czech Industries S.R.O | Solid state forms of tavapadon and processes for preparation thereof |
CN118401513A (zh) * | 2022-01-29 | 2024-07-26 | 苏州科睿思制药有限公司 | 他伐帕敦的晶型及其制备方法和用途 |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5025142B1 (fr) | 1969-07-30 | 1975-08-21 | ||
JPS5039272B1 (fr) | 1970-07-14 | 1975-12-16 | ||
JPS5025142A (fr) | 1973-07-06 | 1975-03-17 | ||
JPS5039272A (fr) | 1973-08-10 | 1975-04-11 | ||
JPS5516432B2 (fr) | 1974-05-28 | 1980-05-01 | ||
JPS51113899A (en) | 1975-03-27 | 1976-10-07 | Yoshitomi Pharmaceut Ind Ltd | Method for preparing novel tetrazole derivatives |
JPS522031A (en) | 1975-06-24 | 1977-01-08 | Japan Niyuupureito Hokushiyou | Sunshade device |
DE2861615D1 (en) | 1978-01-02 | 1982-03-11 | Ciba Geigy Ag | Phenoxy-alkyl oxazolines, their preparation, compositions containing them and their application as herbicides |
EP0101662A3 (fr) | 1982-06-25 | 1985-12-04 | Ciba-Geigy Ag | Acides benzoylparabanoiques |
US4550108A (en) | 1983-08-17 | 1985-10-29 | Ciba Geigy Corporation | 1,3,5-Oxadiazine-2,4-diones and pesticidal use |
US4723015A (en) | 1983-10-17 | 1988-02-02 | Ciba-Geigy Corporation | Certain insecticidal N-2-pyridyloxyphenylbenzimidates |
IL73611A0 (en) | 1983-12-06 | 1985-02-28 | Nippon Soda Co | 1,2,4-oxa-and thiadiazolin-3-one derivatives,their preparation and their use as insecticides and fungicides |
JPS61275271A (ja) | 1985-05-30 | 1986-12-05 | Nippon Soda Co Ltd | 1,2,4−オキサ(チア)ジアゾリン誘導体、その製造方法,殺虫剤及び農園芸用殺菌剤 |
DE3545786A1 (de) | 1985-12-21 | 1987-06-25 | Schering Ag | Pyrazolinderivate, ihre herstellung und ihre verwendung als mittel mit insektizider wirkung |
DE3545569A1 (de) | 1985-12-21 | 1987-06-25 | Hoechst Ag | Neue pyridin-derivate, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als schaedlingsbekaempfungsmittel |
DE3631511A1 (de) | 1986-09-12 | 1988-03-24 | Schering Ag | 5-halogen-1,2,4-triazole, verfahren zu ihrer herstellung und ihre verwendung als akarizide und insektizide mittel |
EP0296518A1 (fr) | 1987-06-22 | 1988-12-28 | Ciba-Geigy Ag | Dérivés de phényléthers comme microbicide, procédé de leur préparation et leur application |
DE3826855A1 (de) * | 1988-08-06 | 1990-02-15 | Cassella Ag | 4,5-dihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und ihre verwendung |
JPH0259574A (ja) | 1988-08-23 | 1990-02-28 | Mitsubishi Kasei Corp | ピラジノン誘導体又はその塩類 |
JPH0259573A (ja) | 1988-08-23 | 1990-02-28 | Mitsubishi Kasei Corp | 2(1h)−ピリミジノン誘導体又はその塩類 |
US5066667A (en) | 1989-06-26 | 1991-11-19 | Ciba-Geigy Corporation | Thioxotetrazolines and insecticidal use thereof |
DE69104071T2 (de) | 1990-01-18 | 1995-05-11 | Nissan Chemical Ind Ltd | Uracilderivate und Pestizide, die diese als wirksame Stoffe enthalten. |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
JPH03261783A (ja) | 1990-03-12 | 1991-11-21 | Suntory Ltd | 1,2,4―トリアジンジオン化合物及びそれを有効成分とする抗コクシジウム剤 |
DE4030042A1 (de) | 1990-05-17 | 1991-11-21 | Bayer Ag | Verwendung von substituierten 1,2,4-triazindionen |
JP3018422B2 (ja) | 1990-07-27 | 2000-03-13 | 日東紡績株式会社 | 床 材 |
US5630962A (en) | 1990-12-19 | 1997-05-20 | Hoechst Aktiengesellschaft | 2-Fluoropyridines, their preparation and their use in liquid crystal mixtures |
JPH0539272A (ja) | 1991-01-09 | 1993-02-19 | Nissan Chem Ind Ltd | ピリミジンジオン誘導体および除草剤 |
JPH0525142A (ja) | 1991-07-12 | 1993-02-02 | Nissan Chem Ind Ltd | ウラシル誘導体及び有害生物防除剤 |
JPH05202031A (ja) | 1992-01-28 | 1993-08-10 | Nissan Chem Ind Ltd | N−アミノピリミジンジオン誘導体および除草剤 |
EP0630370A1 (fr) | 1992-03-11 | 1994-12-28 | E.I. Du Pont De Nemours And Company | Oxazolidinones fongicides |
US5482951A (en) | 1992-05-29 | 1996-01-09 | Kumiai Chemical Industry Co., Ltd. | Triazole derivatives as well as insecticide and acaricide |
JPH07501084A (ja) | 1992-08-31 | 1995-02-02 | チバ−ガイギー アクチェンゲゼルシャフト | 4,5−ジシアノイミダゾール誘導体及びそれらを含む農薬(pesticidal)組成物 |
KR0151364B1 (ko) | 1992-12-25 | 1998-10-15 | 시모무라 도오루 | 헤테로 고리 유도체 및 유해 생물 방제제 |
JP3261783B2 (ja) | 1993-02-04 | 2002-03-04 | ミノルタ株式会社 | 光変調素子 |
JP3682075B2 (ja) | 1993-04-16 | 2005-08-10 | クミアイ化学工業株式会社 | トリアゾール誘導体及び殺虫、殺ダニ剤 |
WO1995004724A1 (fr) | 1993-08-11 | 1995-02-16 | Nippon Soda Co., Ltd. | Derive d'imidazole et son procede de production, et substance anti-nuisibles |
JPH0873446A (ja) | 1994-04-22 | 1996-03-19 | Nippon Soda Co Ltd | ヘテロ環化合物および殺虫・殺ダニ剤 |
JPH0827120A (ja) | 1994-07-08 | 1996-01-30 | Nissan Chem Ind Ltd | テトラヒドロピリミジノン誘導体 |
JPH08217777A (ja) | 1995-02-10 | 1996-08-27 | Nippon Nohyaku Co Ltd | 2−ピラゾリン−5−オン誘導体及びその中間体並びに除草剤 |
DE19518681A1 (de) | 1995-05-22 | 1996-11-28 | Bayer Ag | Verfahren zur Herstellung von 5,6-Dihydro-1,3-oxazinen |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
JPH09291282A (ja) | 1996-04-26 | 1997-11-11 | Sumitomo Chem Co Ltd | 安定化した液晶材料およびこれを用いた液晶素子 |
WO2000035298A1 (fr) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing-gum contenant des agents medicamenteux actifs |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
AU749237B2 (en) * | 1997-10-27 | 2002-06-20 | Isk Americas Incorporated | Substituted benzene compounds, process for their preparation, and herbicidal and defolient compositions containing them |
US6521641B1 (en) | 1998-10-08 | 2003-02-18 | Allergan, Inc. | Male anti-fertility agents |
US6413992B1 (en) | 1998-10-23 | 2002-07-02 | Dow Agrosciences Llc | 3-(substituted pyridyl)-1,2,4-triazole compounds |
GB9903671D0 (en) | 1999-02-17 | 1999-04-14 | Cenes Ltd | Dopamine D-1 receptor agonist compounds |
BR0107662A (pt) | 2000-01-18 | 2002-11-19 | Pfizer Prod Inc | Antagonistas do fator de liberação de corticotropina |
MXPA02009763A (es) | 2000-04-04 | 2003-03-27 | Shionogi & Co | Composiciones aceitosas las cuales contienen farmacos altamente solubles en grasa. |
JP2004501913A (ja) | 2000-06-23 | 2004-01-22 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | ヘテロアリール−フェニル置換Xa因子阻害剤 |
US6476055B1 (en) | 2001-03-28 | 2002-11-05 | Nippon Soda Co. Ltd. | 5,5-disubstituted thiazolidine derivative pesticides |
US7501429B2 (en) | 2001-04-11 | 2009-03-10 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
US20020193403A1 (en) | 2001-05-03 | 2002-12-19 | Allergan Sales, Inc. | Methods of treating hyperlipidemia |
BR0209499A (pt) | 2001-05-09 | 2004-07-06 | Sumitomo Chem Takeda Agro Co | Composto, processo para produzir o composto, e, composição pesticida |
AR036873A1 (es) | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
US7998986B2 (en) | 2001-12-21 | 2011-08-16 | Exelixis Patent Company Llc | Modulators of LXR |
WO2003079986A2 (fr) | 2002-03-18 | 2003-10-02 | Bristol-Myers Squibb Company | Derives d'uracile utilises en tant qu'inhibiteurs de l'enzyme tnf-alpha convertase (tace) et metalloproteases matricielles |
BR0313943A (pt) | 2002-08-26 | 2005-08-02 | Nissan Chemical Ind Ltd | Composto benzanilida substituìdo e agente de controle de organismo nocivo |
CA2505361A1 (fr) | 2002-11-11 | 2004-05-27 | Bayer Healthcare Ag | Derives de phenyl- ou heteroarylamino-alcanes comme antagonistes du recepteur ip |
US20040171075A1 (en) | 2002-12-31 | 2004-09-02 | Flynn Daniel L | Modulation of protein functionalities |
MXPA05012281A (es) | 2003-05-14 | 2006-05-19 | Torreypines Therapeutics Inc | Compuestos y uso de los mismos en la modulacion beta amiloide. |
US6969744B2 (en) | 2003-06-19 | 2005-11-29 | University Of Southern Mississippi | Living and quasiliving cationic telechelic polymers quenched by N-substituted pyrrole and methods for their preparation |
EP1663979B1 (fr) | 2003-09-03 | 2013-10-09 | RaQualia Pharma Inc. | Composes de phenyle ou de pyridyle amide utiles comme antagonistes de la prostaglandine e2 |
WO2005051932A1 (fr) | 2003-11-28 | 2005-06-09 | Nippon Soda Co., Ltd. | Derive arylheterocycle, bactericide et insecticide agricoles ou horticoles |
JP2005272452A (ja) | 2004-02-23 | 2005-10-06 | Nissan Chem Ind Ltd | 置換ベンズアニリド化合物及び有害生物防除剤 |
EP1740211A2 (fr) | 2004-04-20 | 2007-01-10 | Pfizer Products Incorporated | Combinaisons contenant des ligands de alpha-2-delta |
EP1751136B1 (fr) | 2004-05-07 | 2014-07-02 | Amgen Inc. | Derives heterocycliques nitrogenes comme modulateurs de proteines kinases et leurs utilisations pour le traitement de l' angiogenese et le cancer |
TW200612827A (en) | 2004-08-25 | 2006-05-01 | Sumitomo Chemical Co | Insecticide composition |
WO2007016431A2 (fr) * | 2005-07-29 | 2007-02-08 | Concert Pharmaceuticals Inc. | Nouveaux derives de benzo[d][1,3]-dioxol |
US7973060B2 (en) | 2005-10-13 | 2011-07-05 | Crystalgenomics, Inc. | Fab I inhibitor and process for preparing same |
GB0524786D0 (en) | 2005-12-05 | 2006-01-11 | Glaxo Group Ltd | Compounds |
US7560551B2 (en) | 2006-01-23 | 2009-07-14 | Amgen Inc. | Aurora kinase modulators and method of use |
WO2007095603A2 (fr) | 2006-02-15 | 2007-08-23 | Abbott Laboratories | Nouveaux inhibiteurs d'acétyl-coa carboxylase (acc) et leur utilisation dans le traitement du diabète, de l'obésité et du syndrome métabolique |
JP5025142B2 (ja) | 2006-02-27 | 2012-09-12 | 株式会社東芝 | モータ制御装置 |
CA2644368A1 (fr) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Derive heterocyclique azote et agent pharmaceutique comprenant le derive en tant que principe actif |
TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途 |
JP2009535307A (ja) | 2006-04-28 | 2009-10-01 | アベキサ・リミテッド | インテグラーゼ阻害剤3 |
CA2663901A1 (fr) | 2006-09-21 | 2008-03-27 | Piramal Life Sciences Limited | Derives de la pyridine pour le traitement de troubles du metabolisme en lien avec la resistance a l'insuline ou a l'hyperglycemie |
US20090318465A1 (en) | 2006-09-21 | 2009-12-24 | Rosalind Adaikalasamy Marita | Method for identifying compounds that act as insulin-sensitizers |
EP2090577B1 (fr) | 2006-10-19 | 2017-04-05 | Signal Pharmaceuticals, LLC | Composés héteroaryliques, compositions les contenant et leur utilisation en tant qu'inhibiteurs de protein kinases |
EP1916240A1 (fr) * | 2006-10-25 | 2008-04-30 | Syngeta Participations AG | Nouveaux derivés de pyridazine |
DE102007003036A1 (de) | 2006-12-20 | 2008-06-26 | Bayer Cropscience Ag | Pyrimidinylpyrazole |
TW200836743A (en) | 2007-01-29 | 2008-09-16 | Xenon Pharmaceuticals Inc | Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions |
WO2008101682A2 (fr) | 2007-02-22 | 2008-08-28 | Syngenta Participations Ag | Nouveaux microbiocides |
TW200900391A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives |
TW200900065A (en) * | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
CN101294257B (zh) | 2007-04-23 | 2014-06-18 | 株式会社神户制钢所 | 焊接热影响部的韧性优异的钢材及其制造方法 |
JP2009062290A (ja) | 2007-09-04 | 2009-03-26 | Takeda Chem Ind Ltd | シクロプロパン化合物 |
JP5366269B2 (ja) * | 2007-09-14 | 2013-12-11 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 1,3−二置換4−(アリル−x−フェニル)−1h−ピリジン−2−オン |
ES2371308T3 (es) * | 2007-10-31 | 2011-12-29 | Abbott Gmbh & Co. Kg | Compuestos de bencenosulfonamida apropiados para tratar los trastornos que responden a la modulación del receptor d3 de la dopamina. |
US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
EP2274280A2 (fr) | 2008-04-16 | 2011-01-19 | Biolipox AB | Composés bis-aryliques destinés à être utilisés en tant que médicaments |
US20110112193A1 (en) | 2008-05-14 | 2011-05-12 | Peter Nilsson | Bis-aryl compounds for use as medicaments |
EP2328586A2 (fr) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Dérivés pyridazinone substitués comme ligands des récepteurs de l'histamine-3 (h3) |
MX2011000175A (es) | 2008-06-25 | 2011-06-27 | Envivo Pharmaceuticals Inc | Compuestos heterociclicos 1,2-di-substituidos. |
WO2010029299A1 (fr) * | 2008-09-12 | 2010-03-18 | Biolipox Ab | Dérivés de pyrimidinone pour utilisation en tant que médicaments |
WO2010064688A1 (fr) | 2008-12-03 | 2010-06-10 | 日本農薬株式会社 | Dérivés pyrimidines, insecticides pour cultures maraîchères comportant de tels dérivés et leur procédé d’utilisation |
WO2010068788A1 (fr) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amides hétérocycliques en tant qu'inhibiteurs de la btk |
PE20120008A1 (es) | 2009-01-12 | 2012-01-24 | Icagen Inc | Derivados de fenoxi bencenosulfonamida |
EP2246335A1 (fr) | 2009-02-17 | 2010-11-03 | Bayer CropScience AG | Aminopyridineamides en tant que pesticides |
MX336711B (es) * | 2010-03-04 | 2016-01-28 | Merck Sharp & Dohme | Inhibidores de catecol o-metil transferasa y su uso en el tratamiento de transtornos psicoticos. |
US8927561B2 (en) | 2010-04-23 | 2015-01-06 | Kineta, Inc. | Pyrimidinedione anti-viral compounds |
KR20120018236A (ko) | 2010-07-23 | 2012-03-02 | 현대약품 주식회사 | 치환된 피리미디닐 유도체 및 이의 제조방법 |
MY165908A (en) | 2010-08-10 | 2018-05-18 | Takeda Pharmaceuticals Co | Heterocyclic compound and use thereof |
CN103153955A (zh) | 2010-09-17 | 2013-06-12 | 普渡制药公司 | 吡啶化合物及其用途 |
AU2012300567B2 (en) | 2011-09-02 | 2016-03-10 | Purdue Pharma L.P. | Pyrimidines as sodium channel blockers |
EA201500402A1 (ru) * | 2012-11-08 | 2016-05-31 | Пфайзер Инк. | Гетероароматические соединения в качестве лигандов допамина d1 |
US20150291625A1 (en) | 2012-11-08 | 2015-10-15 | Pfizer Inc. | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands |
WO2014119770A1 (fr) * | 2013-01-30 | 2014-08-07 | 住友化学株式会社 | Composé pyridazinone et herbicide comprenant celui-ci |
MX2020013099A (es) * | 2013-06-27 | 2022-07-26 | Pfizer | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina. |
-
2014
- 2014-06-13 MX MX2020013099A patent/MX2020013099A/es unknown
- 2014-06-13 ES ES14739554T patent/ES2729630T3/es active Active
- 2014-06-13 PL PL14739554T patent/PL3013813T3/pl unknown
- 2014-06-13 WO PCT/IB2014/062217 patent/WO2014207601A1/fr active Application Filing
- 2014-06-13 DK DK18180416.2T patent/DK3421462T3/da active
- 2014-06-13 TN TN2015000547A patent/TN2015000547A1/fr unknown
- 2014-06-13 CN CN201480036014.7A patent/CN105324376B/zh active Active
- 2014-06-13 DK DK14739554.5T patent/DK3013813T3/da active
- 2014-06-13 PL PL18180416.2T patent/PL3421462T3/pl unknown
- 2014-06-13 TR TR2019/07981T patent/TR201907981T4/tr unknown
- 2014-06-13 PT PT14739554T patent/PT3013813T/pt unknown
- 2014-06-13 MA MA38661A patent/MA38661A1/fr unknown
- 2014-06-13 FI FIEP18180416.2T patent/FI3421462T3/fi active
- 2014-06-13 CU CUP2015000180A patent/CU24334B1/es unknown
- 2014-06-13 EP EP18180416.2A patent/EP3421462B1/fr active Active
- 2014-06-13 NZ NZ713762A patent/NZ713762A/en not_active IP Right Cessation
- 2014-06-13 SG SG11201509186TA patent/SG11201509186TA/en unknown
- 2014-06-13 PE PE2015002614A patent/PE20160664A1/es unknown
- 2014-06-13 AU AU2014300673A patent/AU2014300673B2/en active Active
- 2014-06-13 PT PT181804162T patent/PT3421462T/pt unknown
- 2014-06-13 MD MDA20150122A patent/MD20150122A2/ro not_active Application Discontinuation
- 2014-06-13 CA CA2916653A patent/CA2916653C/fr active Active
- 2014-06-13 RS RS20190843A patent/RS59018B1/sr unknown
- 2014-06-13 HU HUE18180416A patent/HUE062265T2/hu unknown
- 2014-06-13 RS RS20230446A patent/RS64342B1/sr unknown
- 2014-06-13 JP JP2015563113A patent/JP6026024B2/ja active Active
- 2014-06-13 AP AP2015008844A patent/AP2015008844A0/xx unknown
- 2014-06-13 EP EP14739554.5A patent/EP3013813B1/fr active Active
- 2014-06-13 KR KR1020157036343A patent/KR101781723B1/ko active IP Right Grant
- 2014-06-13 HR HRP20230546TT patent/HRP20230546T1/hr unknown
- 2014-06-13 ES ES18180416T patent/ES2948192T3/es active Active
- 2014-06-13 UA UAA201510712A patent/UA112945C2/uk unknown
- 2014-06-13 HU HUE14739554A patent/HUE043705T2/hu unknown
- 2014-06-13 EA EA201592146A patent/EA028637B1/ru unknown
- 2014-06-13 BR BR122023004130-5A patent/BR122023004130B1/pt active IP Right Grant
- 2014-06-13 MX MX2015017169A patent/MX2015017169A/es unknown
- 2014-06-23 US US14/311,963 patent/US9527831B2/en active Active
- 2014-06-24 TW TW103121727A patent/TWI508957B/zh active
- 2014-06-26 UY UY0001035628A patent/UY35628A/es not_active Application Discontinuation
- 2014-06-26 AR ARP140102420A patent/AR096748A1/es unknown
-
2015
- 2015-03-04 US US14/638,608 patent/US9139561B2/en active Active
- 2015-03-04 US US14/638,677 patent/US9107923B2/en active Active
- 2015-10-30 PH PH12015502502A patent/PH12015502502A1/en unknown
- 2015-11-05 IL IL242480A patent/IL242480B/en active IP Right Grant
- 2015-11-09 ZA ZA2015/08252A patent/ZA201508252B/en unknown
- 2015-12-03 CR CR20150634A patent/CR20150634A/es unknown
- 2015-12-18 DO DO2015000302A patent/DOP2015000302A/es unknown
- 2015-12-22 GT GT201500350A patent/GT201500350A/es unknown
- 2015-12-22 NI NI201500179A patent/NI201500179A/es unknown
- 2015-12-24 CL CL2015003735A patent/CL2015003735A1/es unknown
-
2016
- 2016-01-22 EC ECIEPI20163103A patent/ECSP16003103A/es unknown
- 2016-03-23 HK HK16103425.1A patent/HK1215435A1/zh unknown
- 2016-11-11 US US15/349,075 patent/US9822097B2/en active Active
-
2017
- 2017-10-10 US US15/729,111 patent/US10093655B2/en active Active
-
2018
- 2018-09-06 US US16/123,072 patent/US10421744B2/en active Active
-
2019
- 2019-06-27 HR HRP20191163TT patent/HRP20191163T1/hr unknown
- 2019-08-13 US US16/539,865 patent/US10696658B2/en active Active
-
2020
- 2020-05-21 US US16/880,632 patent/US11014909B2/en active Active
-
2021
- 2021-03-17 US US17/204,095 patent/US11964961B2/en active Active
-
2024
- 2024-03-18 US US18/607,834 patent/US20240317713A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38661A1 (fr) | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine | |
MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
MA42295B1 (fr) | Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation | |
MA35342B1 (fr) | Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase | |
MA41562A1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
MA42239B1 (fr) | Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant | |
MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
MA35826B1 (fr) | Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk | |
MA45222A (fr) | Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
MA37762A1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
MA38138A1 (fr) | Dérivés inédits de quinolone | |
MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
MA38069A1 (fr) | Composés hétéroaromatiques utilisés comme ligands de la dopamine d1 | |
MA31710B1 (fr) | (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament | |
MA38999A1 (fr) | Nouveaux composés hétérocycliques | |
MA37439A1 (fr) | Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1). | |
MA54386B1 (fr) | Modulateurs de trex1 | |
MA50013B1 (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton | |
MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
MA31834B1 (fr) | 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires | |
MA38679B1 (fr) | Modulateurs du récepteur de cxcr7 | |
MA38410B1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine |